Zeroing in on Xylazine

References (11)

1. Robbins-Welty G, Hart J, Dussault N, et al. Xylazine masking benzodiazepine withdrawal. Prim Care Companion CNS Disord. 2024;26(1):23cr03619. PubMed CrossRef
2. Zagorski CM, Hosey RA, Moraff C, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141. PubMed
3. Reyes JC, Negrón JL, Colón HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519–526. PubMed CrossRef
4. Gupta R, Holtgrave DR, Ashburn MA. Xylazine – medical and public health imperatives. N Engl J Med. 2023;388(24):2209–2212. PubMed CrossRef
5. Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, et al. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8. PubMed
6. Hoffmann U, Meister CM, Golle K, et al. Severe intoxication with the veterinary tranquilizer xylazine in humans. J Anal Toxicol. 2001;25:245–249. PubMed CrossRef
7. Malaca S, Pesaresi M, Kapoor A, et al. Pharmacology and toxicology of xylazine: quid novum? Eur Rev Med Pharmacol Sci. 2023;27:7337–7345. PubMed CrossRef
8. Leconte CE, Sethi R. The appearance of xylazine in the United States as a fentanyl adulterant. Prim Care Companion CNS Disord. 2023;25(6):22nr03473. PubMed CrossRef
9. Smith MA, Biancorosso SL, Camp JD, et al. “Tranq dope” overdose and mortality: lethality induced by fentanyl and xylazine. bioRxiv. 2023. doi:10.1101/2023.09.25.559379 CrossRef
10. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. PubMed CrossRef
11. Pergolizzi J Jr., Lequang JAK, Magnusson P, et al. The new stealth drug on the street: a narrative review of xylazine as a street drug. Cureus. 2023;15:e40983. PubMed CrossRef